Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Navtemadlin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2024
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : European Network for Gynaecological Oncological Trial Groups | GOG Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Details : Navtemadlin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Endometrial Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : European Network for Gynaecological Oncological Trial Groups | GOG Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Navtemadlin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Kartos Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics
Details : Kartos is collaborating with Tempus to use the xT assay, a 648-gene panel, to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may benefit from treatment with KRT-232 (navtemadlin, a small molecule MDM2 inhibitor).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 06, 2022
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Kartos Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Details : KRT-232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Details : KRT-232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2021
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Illumina
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The initial focus of the collaboration will be the co-development of multiple CDx claims in blood cancers for Kartos’ KRT-232, a potent and selective oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 24, 2021
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Illumina
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Details : KRT-232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2021
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Telios Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KRT-232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Telios Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KRT-232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Navtemadlin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable